Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients

Antiviral Therapy

Volumn 16, Issue 2, 2011, Pages 199-205

  Thibault, Vincent ^a,b   Stitou, Hind ^a   Desire, Nathalie ^b   Valantin, Marc Antoine ^a   Tubiana, Roland ^a   Katlama, Christine ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PROTEINASE INHIBITOR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; DNA DETERMINATION; DNA REPLICATION; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS LOAD;

ADENINE; ADULT; AGED; ANTI-HIV AGENTS; FOLLOW-UP STUDIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; YOUNG ADULT;

EID: 79953211875     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1723     Document Type: Article

References (21)

1. Larsen C, Pialoux G, Salmon D, et al. [Prevalence of hepatitis B and C virus infections in HIV infected patients, France, June 2004]. Bulletin Epidémiologique Hebdomadaire 2005; 23:109-112. French.
2. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-88. (Pubitemid 351228130)
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
4. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750-1758. (Pubitemid 38736340)
5. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA declineand HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44:675-684. (Pubitemid 44433724)
6. Volz T, Lutgehetmann M, Wachtler P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133:843-852. (Pubitemid 47374140)
7. Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006; 44:694-702. (Pubitemid 44433726)
8. Jaroszewicz J, Serrano BC, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52:514-522.
9. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52:508-513.
10. Lu L, Ye D, Wang Y, et al. Relationship between HBV cccDNA and HBsAg levels is associated with HBeAg statuses of chronic hepatitis B patients. J Hepatol 2009; 50 Suppl 1:S209.
11. Quasdorff M, Protzer U. Control of hepatitis B virus at the level of transcription. J Viral Hepat 2010; 17:527-536.
12. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318-1326.
13. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49:1141-1150.
14. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49:1151-1157.
15. Iavarone M, Lampertico P, Vigano M, et al. Progressive decline of HBsAg titers in long-term virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B. J Hepatol 2009; 50 Suppl 1:S331.
16. Takkenberg B, Zaaijer H, Weegink C, et al. Baseline HBsAg level predict HBsAg loss in chronic hepatitis b patients treated with a combination of peginterferon alfa-2a and adefovir: an interim analysis. J Hepatol 2009; 50 Suppl 1:S8.
17. Manesis EK, Schina M, Le Gal F, et al. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Antivir Ther 2007; 12:381-388. (Pubitemid 46787983)
18. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64:51-68. (Pubitemid 30143840)
19. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol 2006; 87:1439-1449. (Pubitemid 43827198)
20. Gane E, Heathcote EJ, Marcellin P, et al. HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment. J Hepatol 2010; 52 Suppl 1:S388.
21. + chronic hepatitis B patients with 3 years of telbivudine treatment during the Globe study. J Hepatol 2009; 50 Suppl 1:S9.